Frank Rimerman Advisors’s GSK GSK Stock Holding History

Frank Rimerman Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$764K	Sell	14,570 -702	-5%	-$37.1K	0.04%	312
2026 Q1	$843K	Sell	15,272 -138	-0.9%	-$7.48K	0.06%	272
2025 Q4	$756K	Buy	15,410 +1,866	+14%	+$87K	0.05%	293
2025 Q3	$585K	Buy	13,544 +6,083	+82%	+$238K	0.04%	333
2025 Q2	$287K	Buy	+7,461	New	+$285K	0.02%	467
2024 Q3	–	Sell	-21,359	Closed	-$822K	–	541
2024 Q2	$822K	Buy	+21,359	New	+$898K	0.06%	248

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Frank Rimerman Advisors's GSK Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its GSK (GSK) stake by 4.6% in Q2 2026, selling an estimated $37.1K and leaving 14,570 shares worth $764K. The position accounts for 0.04% of the portfolio, ranked #312.

Frank Rimerman Advisors first reported a position in GSK in Q2 2024 and has held it in 6 quarters since. The position peaked at $843K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Frank Rimerman Advisors held 14,570 shares of GSK worth $764K as of Q2 2026.
Frank Rimerman Advisors sold 702 GSK shares in Q2 2026, an estimated $37.1K.
GSK made up 0.04% of Frank Rimerman Advisors's portfolio in Q2 2026, its #312 holding.
Frank Rimerman Advisors first reported a position in GSK in Q2 2024 and has held it in 6 quarters since.
Frank Rimerman Advisors's GSK position peaked at $843K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.